Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Denali Therapeutics Inc (NQ: DNLI ) 21.06 -1.06 (-4.79%) Streaming Delayed Price Updated: 3:35 PM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Denali Therapeutics Inc < Previous 1 2 Next > Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies June 03, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights May 07, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial May 01, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights February 27, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces $500 million Private Placement Equity Financing February 27, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™ February 07, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™ February 01, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases January 08, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights November 07, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023 August 30, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights August 08, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome) June 20, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential May 18, 2023 These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. Via MarketBeat Exposures Product Safety Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights May 08, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta April 12, 2023 Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting April 10, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights February 27, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™ February 22, 2023 From Denali Therapeutics Inc. Via GlobeNewswire 3 More Mid-Cap Biotechs The Street Sees Doubling February 22, 2023 According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. Via MarketBeat Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™ February 15, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi January 25, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases January 09, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial December 05, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights November 03, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN November 01, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares October 24, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock October 19, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Denali Therapeutics Announces Proposed Offering of Common Stock October 18, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations October 03, 2022 From Denali Therapeutics Inc. Via GlobeNewswire R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions June 29, 2022 Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... Via FinancialNewsMedia < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.